Richard Alexander Collins - Nov 14, 2025 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
Director
Signature
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Richard Alexander Collins
Stock symbol
DXCM
Transactions as of
Nov 14, 2025
Transactions value $
-$171,599
Form type
4
Date filed
11/17/2025, 05:52 PM
Previous filing
Nov 10, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Collins Richard Alexander Director 6340 SEQUENCE DRIVE, SAN DIEGO /s/ Jereme M. Sylvain, as Attorney-in-Fact for Richard Alexander Collins 2025-11-18 0001700619

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Sale -$172K -2.91K -7.65% $59.05 35.1K Nov 14, 2025 by Trust F1, F2
holding DXCM Common Stock 5.07K Nov 14, 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On August 7, 2025, the Richard A. Collins Revocable Trust (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2 Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee.
F3 Represents unvested restricted stock units which were granted on May 8, 2025 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.